MentionFox
Home › funding signals › TenNor Therapeutics (Suzhou) Ltd
Form D · on the record

TenNor Therapeutics (Suzhou) Ltd — $14.70M Form D filing, May 2026

TenNor Therapeutics (Suzhou) Ltd filed a Form D with the Securities and Exchange Commission on 2026-05-26.

Get the full cited report on TenNor Therapeutics (Suzhou) Ltd

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

See a sample report

Just raised? Share it.

TenNor Therapeutics (Suzhou) Ltd: Raised $14.70M, Form D filed 2026-05-26

What do you want to do with TenNor Therapeutics (Suzhou) Ltd?

Key facts

  • · Form D filed with the SEC · Form D
  • · Sold to date: $14.70M · Form D
  • · Total offering: $14.70M · Form D
  • · First sale: 2026-05-12 · Form D
  • · Investors already in: 1 · Form D

TenNor Therapeutics (Suzhou) Ltd

New Form D on file · 2026-05-26 · the record

$14.70M
raise on the record
D
filing
1
investors in
CHINA
based
Open the record →

What the record says

FilingForm D
Filed2026-05-26
Industry groupBiotechnology
Entity typeCorporation
Incorporated inCHINA
BasedSUZHOU, CHINA
CIK2136090
Accession0001104659-26-066134
Biotechnology · by week
This raise, $14.70M, filed week of May 25

Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $14.70M, on the same scale — one filing against the whole group's total, so it sits low by construction.

Want the whole picture on TenNor Therapeutics (Suzhou) Ltd?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on TenNor Therapeutics (Suzhou) Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on TenNor Therapeutics (Suzhou) Ltd covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    1 cited source found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on Target: the verdict, 16 sections, 39 cited sources, dated 2026-09-28A real finished report, first screen. Opens in a new tab.

The full profile

Checking your access…

Is this you?

If you're behind TenNor Therapeutics (Suzhou) Ltd: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. FoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.

Sourced from the filing index on sec.gov.

Follow this companyRSS

Tools for this story

Each opens in a new tab, filled in for TenNor Therapeutics (Suzhou) Ltd. With no account yet, you sign up free and land on the result.

Cite this page

Permanent URL: https://mentionfox.com/funding/tennor-therapeutics-suzhou-ltd-form-d-26000001
Last updated 2026-09-26
Primary record: SEC filing 1 · SEC filing 2
TenNor Therapeutics (Suzhou) Ltd raised $14.70M — SEC Form D filing, May 2026. MentionFox, 2026-09-26. https://mentionfox.com/funding/tennor-therapeutics-suzhou-ltd-form-d-26000001